San Antonio Breast Cancer Symposium

Pathologic complete response (pCR) to neoadjuvant chemotherapy had a significant correlation with survival in early HER2-positive breast cancer after 4 years of follow-up.

HER2-positive breast cancer may not only be immunogenic but treatment with trastuzumab may also relieve suppression of antitumor immunity, according to new data presented by Sherene Loi, MD, PhD.

According to an analysis of key screening studies presented at the 2013 San Antonio Breast Cancer Symposium, the benefit of screening mammography is more consistent across studies than has previously been thought.

Many important issues will be addressed in the presentations at the 36th San Antonio Breast Cancer Symposium (SABCS), held annually in San Antonio, Texas, this year December 10-14.